One should not forget that despite fragmentation and subclassification of histologic diagnoses in oncology on a genotypic level to assign the best treatment (e.g., KRAS, NRAS, or BRAF, in mutated CRC [58]), the majority of these are captured under the umbrella of a few blood based TMs on a phenotypic level (e.g., CEA and CA19-9 in CRC). This evidence concerns the gene KRAS and colorectal carcinoma.